PatientsVille.com Logo


Prolastin-c Medical Research Studies

Up-to-date List of Prolastin-c Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Prolastin-c Medical Research Studies

Rank Status Study
1 Recruiting Randomized Trial of Exercise on Lower Extremity Edema After Lymphadenectomy in Gynecologic Cancer
Condition: Gynecologic Cancer
Intervention: Other: Pelvic and lower extremity exercise
Outcome Measures: Change in lower extremity edema-related symptoms after pelvic and lower extremities exercise;   the compliance rate of management guidelines for lower extremity edema, the performance rate for pelvic and lower extremity exercise
2 Unknown  Association Study of Genetic Polymorphisms of Candidate Genes With Thiazolidinedione-Related Peripheral Edema and Drug Responsiveness
Condition: Diabetes Mellitus
Outcome Measure: we plan to conduct a case-control study to test the association between single nucleotide polymorphisms (SNPs) in certain candidate genes and TZDs related peripheral edema
3 Recruiting Does NMES Help Relieve Lower Limb Oedema and Improve Joint Mobility and Skin Tissue Oxygenation Levels?
Condition: Oedema
Intervention: Device: Duo-STIM neuromuscular electrical stimulator
Outcome Measures: Oedema Reduction;   Joint Mobility;   Skin Oxygenation
4 Recruiting Pilot Study of PEMF Therapy in Treatment of Post-operative Pain Following Total Knee Arthroplasty
Condition: Post-Operative Pain Following Total Knee Arthroplasty
Interventions: Device: Pulsed Electromagnetic Field Device (Provant);   Device: Sham Pulsed Electromagnetic Field Device
Outcome Measures: Change in Pain Intensity;   Knee Injury and Osteoarthritis Outcome Score (KOOS);   Beck Depression Inventory (BDI);   Patient Global Impression of Change (PGIC);   Analgesic Consumption;   Range of Motion (ROM);   Peripheral Edema
5 Unknown  Compression Aided Management of Edema in Patients With C3 Venous Disease
Condition: Chronic Venous Disease
Interventions: Device: Anti-embolism Knee High Stocking;   Device: 20-30 Knee High Compression Stocking
Outcome Measures: Edema reduction measured by bio-impedance;   Clinical Venous Severity Score Improvement in QOL
6 Unknown  Recombinant Human Growth Hormone During Rehabilitation From Traumatic Brain Injury.
Condition: Traumatic Brain Injury
Interventions: Drug: Recombinant human Growth Hormone;   Drug: Placebo
Outcome Measures: Treatment with recombinant human Growth Hormone (rhGH) in the subacute period after TBI results in improved functional outcome 6 months after injury, as measured by the Composite Outcome Score of the TBI Clinical Trials Network .;   Treatment with rhGH results in increased IGF-1 levels.;   Benefits of rhGH treatment persist up to 1 year after injury;   Low GH response to L-arginine stimulation at baseline is associated with poor functional outcome.;   Low IGF-1 levels at baseline are associated with poor functional outcomes.;   rhGH treatment is more effective in patients who have low IGF-1 levels at baseline.;   rhGH treatment is more effective in patients who have low GH response to L-Arginine stimulation at baseline.;   rhGH treatment in during rehabiliation fromTBI is not associated with increased rate of diabetes mellitus, arthralgias, or peripheral edema.
7 Not yet recruiting Optimization of the Treatment of Acute HF by a Non Invasive Cardiac System-a Randomized Control Trial
Conditions: Heart Failure;   Kidney Injury
Intervention: Device: Hemodynamic group
Outcome Measures: Renal function deterioration during hospitalization;   30 days rehospitalization due to decompensated heart failure;   Length of hospitalization;   All cause mortality at 30 days;   All cause mortality at 3 months;   All cause rehospitalization at 3 months;   Heart failure rehospitalization at 3 months;   Weight Loss during hospitalization - changes in body weight and net fluid loss;   Health-Related Quality of Life and Functional Status - patient-reported dyspnea;   Usage of mechanical ventilation;   Change in BNP/ pro-BNP from baseline to discharge Peak Troponin during the hospitalization;   Free from congestion (defined as jugular venous pressure of <8 cm, with no orthopnea and with trace peripheral edema or no edema) at 72 hours;   Emergency room visit within 60 days
8 Recruiting Recombinant Human Hyaluronidase in Treating Lymphedema in Patients With Cancer
Conditions: Lymphedema;   Malignant Neoplasm
Interventions: Biological: recombinant human hyaluronidase;   Other: laboratory biomarker analysis;   Other: pharmacological study
Outcome Measures: Incidence of adverse events graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0;   Overall response rate defined as the proportion of patients obtaining >= 20% reduction in excess forearm lymphedema;   Serum biomarkers;   Plasma concentration of recombinant human hyaluronidase
9 Recruiting Validation of BIVA for Nutritional Assessment in Cirrhotic Patients
Conditions: Liver Cirrhosis;   Malnutrition
Outcome Measures: Evaluation of nutritional status;   Development of complications
10 Recruiting Fluid Balance in Children Undergoing Fontan Surgery
Conditions: Heart Defects, Congenital;   Hypoplastic Left Heart Syndrome
Interventions: Procedure: Pre BCPC;   Procedure: Pre TCPC;   Procedure: BCPC surgery;   Procedure: TCPC
Outcome Measure: Interstitial colloid osmotic pressure
11 Recruiting Validation of a New Method of Limb Volumetry
Conditions: Edema;   Chronic Venous Insufficiency;   Lymphedema
Outcome Measure: Difference between limb volume measured
12 Recruiting Thiazolidinedione (TZD) on the Diabetic Retinopathy and Nephropathy
Condition: Diabetes
Interventions: Drug: Actos (Pioglitazone);   Drug: Acarbose
Outcome Measures: Diabetic retinopathy;   Diabetic nephropathy
13 Unknown  The Distribution of Pressure in the Thorax During Mechanical Ventilation and Its Effects on the Circulation
Condition: Fluid Responsiveness
Interventions: Other: ventilatory protocol;   Other: Elastic band;   Other: passive leg raising test
Outcome Measures: fluid responsiveness;   Pressure distribution in thorax due to mechanical ventilation;   Dynamic indices in pressure support ventilation;   non invasive prediction of fluid responsiveness;   pressure distribution and dynamic indices during spontaneous breathing
14 Recruiting Evaluation of Renal Blood Flow Using Contrast Enhanced Ultrasound for Differential Diagnosis of Acute Kidney Injury in Cirrhotic Patients: A Pilot Study
Condition: Liver Cirrhosis and Acute Kidney Injury
Intervention: Drug: Definity ultrasound contrast agent
Outcome Measures: To assess the utility of monitoring of RBF using CEU in management of AKI in patients with liver cirrhosis.;   Pattern of blood flow distribution in the kidney in different cases of AKI
15 Recruiting Pioglitazone for Lung Cancer Chemoprevention
Conditions: Lung Cancer;   Endobronchial Dysplasia
Interventions: Procedure: fluorescence bronchoscopy;   Procedure: quantitative high resolution CT scan;   Drug: PIOGLITAZONE VS. PLACEBO 30 mg
Outcome Measure: Changes in endobronchial histology
16 Recruiting Bevacizumab and Peripheral Retinal Changes on Wide Field Angiography in Diabetic Macular Edema
Conditions: Non-proliferative Diabetic Retinopathy;   Proliferative Diabetic Retinopathy;   Diabetic Macular Edema
Intervention: Drug: Bevacizumab
Outcome Measure: Peripheral retinal ischemia
17 Recruiting Peripheral Perfusion Targeted Fluid Management
Conditions: Sepsis;   Severe Sepsis
Intervention: Other: PPTFM
Outcome Measures: Fluid balance during Intensive Care Unit stay;   CRT (Capillary refill time);   Systemic hemodynamic variables;   Respiratory function;   PFI (Peripheral Flow Index);   Tskindiff (Forearm-to-Fingertip temperature skin difference);   StO2 (Peripheral tissue oxygenation)
18 Unknown  ALPI vs Medical Therapy Effects on Optic Nerve Structure & Function
Condition: Glaucoma
Interventions: Procedure: Argon laser Iridoplasty;   Drug: Intravenous acetazolamide
Outcome Measures: optic nerve head stereometric analysis HRT3 and Stratus OCT,optic nerve head and RNFL & macula thickness average. AGIS scores of HVF is the measure of functional status.;   amount and rate of IOP-lowering,gonioscopy and ASOCT changes, change in LOCS grading for cataract, corneal decompensation & edema,macular,retinal edema by Stratus OCT.
19 Recruiting Chemotherapy Induced Peripheral Neuropathy. Could Physical Therapy Help Treat Symptoms?
Conditions: Breast Cancer;   Peripheral Neuropathy, Secondary to Drugs or Chemicals
Intervention: Other: Physical Therapy
Outcome Measures: Change from baseline in Quantitative Sensory Testing;   Number of chemotherapy dose reductions or treatment delays due to severity of nerve pain from the chemotherapy induced neuropathy;   Change from baseline on self-report questionnaire of upper limb function ( Disabilities of the Shoulder, Arm and Hand DASH);   Change from baseline for neuropathic pain measured by the Self reported Leeds Assessment Scale for Neuropathic Symptoms and SIgns (S-LANSS)
20 Unknown  Triple Therapy for Diffuse Diabetic Macular Edema
Condition: Diffuse Diabetic Macular Edema
Intervention: Procedure: Triple therapy for diffuse diabetic macular edema
Outcome Measures: Best-corrected visual acuity (BCVA) and central macular thickness (CMT);   Presence of vitreomacular traction or epimacular membrane, grade of DR, patients age, HbA1c level, BMI, systemic hypertension

These studies may lead to new treatments and are adding insight into Prolastin-c etiology and treatment.

A major focus of Prolastin-c research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Prolastin-c